Ticker Details
Beam Therapeutics Inc.
IPO Date:	February 6, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.07B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.54 | 3.69%
Avg Daily Range (30 D):	$0.84 | 2.95%
Avg Daily Range (90 D):	$0.98 | 3.23%

Institutional Daily Volume
Avg Daily Volume:	1.07M
Avg Daily Volume (30 D):	1.67M
Avg Daily Volume (90 D):	1.8M

Trade Size
Avg Trade Size (Sh.):	59
Avg Trade Size (Sh.) (30 D):	63
Avg Trade Size (Sh.) (90 D):	56

Institutional Trades
Total Institutional Trades:	3,783
Avg Institutional Trade:	$3.19M
Avg Institutional Trade (30 D):	$2.96M
Avg Institutional Trade (90 D):	$3.59M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.14M
Avg Closing Trade (30 D):	$6.32M
Avg Closing Trade (90 D):	$8.26M
Avg Closing Volume:	152.34K

News

Jul 20, 2026 @ 5:30 PM Cathie Wood Is Buying This Up-and-Coming Biotech S... Source: Jeff Siegel

Jul 3, 2026 @ 8:44 AM Gene Editing Therapeutics: Transforming Biopharmac... Source: Researchandmarkets.Com

Jul 3, 2026 @ 8:41 AM Global CRISPR-Based Drug Development Platforms Mar... Source: Researchandmarkets.Com

May 26, 2026 @ 12:35 AM Better Gene-Editing Stock: CRISPR Therapeutics or ... Source: Prosper Junior Bakiny

May 18, 2026 @ 8:00 PM Beam Therapeutics Presents Recently Reported Topli... Source: Beam Therapeutics Inc.

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.68	$-1.18	$-.91
Diluted EPS	$-.68	$-1.18	$-.91
Revenue	$156.04M	$.49M	$31.74M
Gross Profit
Net Income / Loss	$-85.43M	$-122.68M	$-94.32M
Operating Income / Loss	$-378.02M	$-126.55M	$-107.22M
Cost of Revenue
Net Cash Flow	$-62.23M	$-68.45M	$-6.64M
PE Ratio